Longboard Pharmaceuticals to Present New Findings at 15th European Epilepsy Congress
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical firm listed on Nasdaq under the ticker LBPH, is dedicated to creating groundbreaking medicines to treat neurological disorders. The company recently disclosed its participation in the International League Against Epilepsy (ILAE) 15th Annual European Epilepsy Congress, scheduled to be held in Rome, Italy, from September 7-11, 2024.
Dr. Randall Kaye, the Chief Medical Officer of Longboard, highlighted the significance of the ILAE conference, noting its status as a leading event in the epilepsy field. He emphasized that the conference provides an opportunity to engage with key opinion leaders from Europe and around the globe. As Longboard prepares to launch its global Phase 3 program for bexicaserin, the conference will be instrumental in fostering relationships with potential researchers and gathering valuable insights.
One of the notable mentions is the acceptance of Longboard's interim data from the open-label extension of the PACIFIC study as a late-breaking abstract for the conference. The study focuses on the safety and tolerability of bexicaserin in adolescents and adults with Developmental and Epileptic Encephalopathies (DEEs). Dr. Kaye expressed enthusiasm about discussing this data and additional findings that underscore bexicaserin's potential benefits for those living with DEEs.
The event details include several presentations featuring bexicaserin:
1. LATE BREAKER:
- Title: Safety and Tolerability of Bexicaserin in Adolescents and Adults with Developmental and Epileptic Encephalopathies: Interim Results of the Phase 1b/2a PACIFIC Study Open-Label Extension (OLE)
- Event Type: In-Person Posters
- Poster Number: P082
2. Platform Session:
- Title: Efficacy and Safety of Bexicaserin (LP352) in Adolescent and Adult Participants with Developmental and Epileptic Encephalopathies: Results of The Phase 1b/2a PACIFIC Study
- Session: Platform Session – Drug Therapy
- Presentation Time: Sunday, September 8, 2024, from 12:30 PM – 12:38 PM CET
3. In-Person Poster Presentations:
- Title: Bexicaserin has Negligible CYP Or P-glycoprotein Interaction Potential, Minimizing Therapeutic Complexity In Epilepsy Patients with a High Burden of Polypharmacy
- Poster Number: P321
- Title: A Phase 1 Study Of 5-HT2C Superagonist LP352 Shows Robust Brain Penetration, a Strong Correlation Between Plasma and CSF Pharmacokinetics and QEEG Changes Reflecting Receptor Engagement
- Poster Number: P262
- Title: Bexicaserin, A 5-HT2C Superagonist, has Broad Antiepileptic Activity in Preclinical Seizure Models
- Poster Number: P261
Longboard Pharmaceuticals is committed to advancing its portfolio of centrally acting product candidates, which are designed to selectively target specific G protein-coupled receptors (GPCRs). With over two decades of GPCR research, Longboard is focused on pushing forward bexicaserin (LP352), an oral 5-HT2C receptor superagonist that has shown no impact on 5-HT2B and 5-HT2A receptor subtypes, into a global Phase 3 program. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for bexicaserin, aimed at treating seizures related to DEEs in patients aged two years and above. Earlier this year, Longboard reported promising topline results from a Phase 1b/2a clinical trial (the PACIFIC Study) involving bexicaserin for DEEs.
Additionally, Longboard is investigating LP659, an oral modulator of sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5, for potential use in treating rare neuroinflammatory conditions. A Phase 1 single-ascending dose (SAD) clinical trial for LP659 in healthy volunteers has been recently completed.
Both bexicaserin and LP659 are investigational drugs and have not yet received marketing approval from the FDA or any other regulatory bodies.
How to obtain the latest research advancements in the field of biopharmaceuticals?
In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!
